Genetic Insights in Orthopedics Disorders: Paving the Way for Personalized Treatment

Incorporating genetic knowledge into Orthopedics medicine is a significant advancement in personalized healthcare. Genetic factors play a key role in the development, movement, and response to treatment of many Orthopedics conditions [1]. Several conditions, including Osteogenesis imperfecta (OI), Achondroplasia, Marfan syndrome, Ehlers-Danlos syndrome, Charcot-Marie-Tooth disease, and Cleidocranial dysostosis, have well-defined genetic causes, which allows for earlier, more precise diagnoses—particularly through neonatal screening [2]. Although osteoarthritis is often seen as an age-related condition, genetic factors can have a significant influence on when and how severely it develops. Genetic testing could help predict how the disease will progress [3]. This review explores the application of genetics in Orthopedics diseases, aiming on the transformative potential of personalized medicine, as well as the profits and challenges linked with its integration into Orthopedics care.

Genetic Predisposition

Genetics can be helpful in the development of Orthopedics conditions, and numerous studies have pinpointed markers that help explain the causes and risks associated with these conditions [4]. For example, variations in genes like COL2A1 and IL1B are associated with a higher risk of osteoarthritis, which causes joint cartilage breakdown [5]. Another important genetic marker is COL1A1, responsible for collagen type I, a key part of bones and connective tissues. Mutations in this gene are connected to OI, a condition that causes fragile bones [6]. Additionally, changes in the RUNX2 gene, involved in bone development, are linked to cleidocranial dysostosis, a disorder affecting bone and tooth growth. Genetic markers like IL-1B and TNF, which are involved in inflammation, have also been implicated in inflammatory joint conditions such as rheumatoid arthritis and osteoarthritis [7]. Understanding these genetic predispositions admits for early identification and intervention, potentially delaying disease onset or evolution [8].

In addition to disease-specific markers, some genes are associated with broader conditions that impact cartilage, bones, and joints, like osteoarthritis and osteoporosis [9]. For instance, variations in the APOA2 and LPL genes, which play a role in lipid metabolism, have been linked to a higher risk of osteoarthritis. The LRP5 gene, which helps regulate bone density, is linked to both high bone mineral density and conditions like osteoporosis [10]. Additionally, research on rheumatoid arthritis has shown a connection with the HLA-DRB1 gene, which is involved in immune responses and raises the risk of autoimmune diseases [11]. Understanding these genetic markers helps not only in identifying individuals at higher risk for Orthopedics conditions but also in developing personalized treatment strategies. Genetic testing can enhance patient outcomes by predicting susceptibility, tracking disease progression, and guiding personalized treatments [12]. It helps reduce the need for trial-and-error approaches and can inform preventive strategies, like early interventions or lifestyle changes [13].

Pharmacogenomics

Pharmacogenomics is the study of how genetic variations affect an individual’s response to medications, especially in Orthopedics. This area is a key focus for developing personalized pain management plans, as genetic differences can impact how patients metabolize medications used to treat musculoskeletal conditions [14]. For example, variations in the CYP2D6 gene can impact the metabolism of analgesics such as opioids and nonsteroidal antiinflammatory drugs (NSAIDs), which are frequently prescribed to manage pain in conditions like osteoarthritis and rheumatoid arthritis [15]. Genetic variations in the TPMT gene, which affects how the body metabolizes immune-suppressive drugs like methotrexate, can impact how patients respond to treatments for inflammatory joint diseases [16]. By understanding these genetic factors, healthcare providers can customize pain management plans to reduce side effects and enhance treatment effectiveness. Beyond pain and inflammation management, pharmacogenomics also plays a vital role in optimizing bone health treatments. For example, variations in the VDR (vitamin D receptor) gene can meaningfully impact how well patients respond to vitamin D supplements used to treat osteoporosis and other bone disorders [17]. People with specific genetic profiles may have a diminished ability to process vitamin D, which could necessitate adjusted dosages for optimal bone health [18]. Similarly, genetic variations in CYP2D6, involved in metabolizing drugs like bisphosphonates (used to treat osteoporosis), can affect their effectiveness in preventing bone loss [19]. With the increasing accessibility of pharmacogenomic testing, clinicians can use this information to personalize treatments, ensuring that drugs are more effective while minimizing potential risks [20].

Drugs that take into account genetic variations in the VDR gene, such as calcitriol, alfacalcidol, paricalcitol, and doxercalciferol, are designed to optimize the treatment of osteoporosis, rickets, and other bone-related disorders by tailoring vitamin D supplementation to an individual’s genetic profile [21]. These drugs address variations in the VDR gene, which plays a key role in how the body processes vitamin D. For individuals with certain genetic variations, standard doses of vitamin D may not be effective, leading to suboptimal bone health [22]. By developing vitamin D analogs and formulations that match these genetic profiles, pharmaceutical companies can improve the efficacy of treatment, improving bone mineral density, calcium metabolism, and reducing the risk of fractures [23]. This approach aligns with the broader trend toward personalized medicine, where genetic testing helps guide the development of more individualized, effective therapies [24].

Regenerative Medicine

Regenerative medicine in Orthopedics is revolutionizing how we approach the repair and regeneration of damaged tissues, such as bones, cartilage, tendons, and ligaments, caused by injury, disease, or aging [25, 26]. Using advanced techniques like stem cell therapy, gene therapy, and tissue engineering, this field aims to restore function and promote healing [27, 28]. Stem cells, especially mesenchymal stem cells (MSCs), are particularly valuable for their ability to differentiate into various musculoskeletal tissues, aiding in tissue repair. Gene therapy is also being utilized to deliver specific genes that stimulate tissue regeneration, such as growth factors like bone morphogenetic proteins (BMPs), which encourage bone and cartilage formation [29]. By focusing on the body’s natural ability to heal itself, regenerative medicine offers a promising alternative to traditional treatments, such as surgery and implants, especially for degenerative conditions like osteoarthritis and fractures [30]. These cutting-edge therapies are not only increasing recovery times but also improving long-term consequences for patients, offering a more effective and less invasive solution to Orthopedics issues [31].

The integration of genetic engineering in the development of biodegradable materials for Orthopedics is also a growing area of interest. These materials, such as scaffolds, are designed to support bone and tissue repair while being gradually absorbed by the body, eliminating the need for surgical removal [32, 33]. By using genetic engineering, researchers can modify the properties of these materials to develop their compatibility with human tissues and improve the healing process [34]. For instance, incorporating genetically engineered proteins like collagen, fibronectin, or BMPs (bone morphogenetic proteins) into biodegradable scaffolds can optimize their ability to promote cell adhesion, growth, and differentiation [35]. This not only improves tissue regeneration but also ensures that the materials are gradually integrated into the body, making them ideal for Orthopedics applications such as bone repair and cartilage regeneration [36].

Chitosan-based vectors, another promising technology in Orthopedics gene delivery, are being developed for their use in tissue regeneration, particularly in bone and cartilage repair [37]. Chitosan, a biodegradable polysaccharide derived from chitin, serves as a carrier for genes, growth factors, or drugs, and is highly biocompatible and non-toxic [38]. These vectors can be engineered to release therapeutic agents in a controlled manner, making them ideal for targeted treatments in Orthopedics conditions [39]. By modifying chitosan at the genetic level, researchers can enrich its ability to deliver genes that promote bone growth, such as BMP-2, or to correct genetic defects like those seen in OI. The incorporation of genetic modifications allows for more personalized treatment strategies, ensuring that the therapeutic vectors respond to a patient’s unique genetic profile [40]. This targeted approach can improve healing results and reduce complications, further advancing the potential of gene therapy and regenerative medicine in Orthopedics care.

Gene Delivery

Gene delivery, particularly through gene therapy, offers a powerful approach to treating musculoskeletal disorders by introducing, deleting, or modifying genes within a patient’s cells. This technique aims to address the underlying genetic causes of these disorders or to stimulate tissue repair. For example, in conditions like OI, genetic engineering can restore normal bone formation by inserting a functional copy of the COL1A1 gene, which is responsible for collagen production [41]. Additionally, gene therapy can deliver specific genes that promote osteogenesis (bone formation) or chondrogenesis (cartilage formation) using viral vectors or advanced technologies like CRISPR-Cas9. This helps regenerate damaged bone or cartilage, offering hope for improved recovery and long-term results in patients with degenerative diseases or injuries [42].

One promising method of gene delivery is intra-articular injection, where therapeutic genes are directly introduced into the joint space to treat joint diseases such as osteoarthritis, rheumatoid arthritis, and cartilage injuries [43]. This technique uses vectorseither viral or non-viral-to deliver genes that encode for growth factors, like TGF-β and IGF-1, to stimulate cartilage regeneration, or anti-inflammatory cytokines to reduce pain and inflammation [44]. By targeting the genes directly to the affected area, intraarticular gene delivery minimizes systemic side effects and ensures that the therapeutic gene remains concentrated at the site of injury [45]. The effectiveness of this treatment depends not only on the patient’s genetic factors but also on the design of the delivery vectors. Variations in receptor expression or immune responses can influence how well the genes are taken up, but genetic engineering of the delivery vectors can boost their efficiency and precision. By tailoring these vectors to the patient’s genetic profile and joint condition, gene delivery offers a personalized, long-lasting solution for joint repair and regeneration [46].

Stem-Cell-Based Gene Therapy

Stem-cell-based gene therapy has emerged as a promising approach in Orthopedics treatments, offering new possibilities for regenerating damaged musculoskeletal structures. Mesenchymal stem cells (MSCs) are particularly valuable due to their ability to differentiate into various tissues, including bone, cartilage, and muscle [47]. By genetically modifying these stem cells, clinicians can improve their regenerative capabilities, addressing challenges such as poor cell survival and differentiation rates [48]. For example, incorporating genes that encode for growth factors like BMP-2 (bone morphogenetic protein-2) or IGF-1 (insulin-like growth factor 1) into MSCs can accelerate bone healing, making it especially useful in conditions such as fractures or spinal fusions [49]. These advancements offer more personalized and effective treatments, reducing the need for invasive surgeries and improving recovery times, ultimately boosting patient effects [50].

In the context of cartilage regeneration, [51] mentioned that stem-cell-based gene therapy has shown important promise, particularly for conditions like osteoarthritis and rheumatoid arthritis, where the natural ability of cartilage to repair itself is limited. MSCs can be genetically engineered to express specific genes, such as BMP-7, IGF-1, and SOX9, which promote cartilage production at the site of damage. Studies have demonstrated that MSCs engineered to express BMP-7 can successfully regenerate osteochondral defects in animal models [52]. Additionally, the use of transcription factors like Brachyury has enabled the exclusive differentiation of stem cells into chondrocytes, preventing unwanted bone formation [53]. Combining gene therapy with stem cell-based delivery methods, such as using muscle-derived stem cells or periosteal MSCs, has shown promising results in repairing cartilage defects. This targeted, effective approach provides a powerful strategy for treating Orthopedics conditions that are traditionally difficult to address due to cartilage’s limited regenerative capacity [54].

While the integration of genetics into Orthopedics treatments holds great promise for personalized care, it also presents several trade-offs and challenges that need careful consideration [55]. One of the primary challenges is the complexity of genetic interactions, which means that patients with the same genetic marker may experience different disease conclusions [56]. This variability makes it difficult to predict how a patient will respond to a treatment or how a disease will progress based on genetic data alone [57]. Additionally, the psychological impact of receiving genetic risk information cannot be overlooked. For some patients, learning about genetic predispositions to conditions like osteoarthritis or osteoporosis may cause anxiety, stress, or a sense of fatalism, which could negatively affect their mental health and treatment adherence [58]. To address these issues, it is required to approach genetic testing with a nuanced understanding, providing counselling and support to help patients process their genetic information and make informed decisions about their care [59].

Another major barrier to the widespread implementation of genetic applications in Orthopedics is the cost and accessibility of genetic testing. Advanced genetic technologies, such as CRISPRCas9 and personalized drug development, can be expensive, limiting access to only a small group of patients [60]. This financial constraint, along with limited access to genetic testing in certain regions, can prevent equitable access to personalized Orthopedics care [61]. Furthermore, integrating genetic data into current healthcare frameworks requires close collaboration among geneticists, Orthopedics specialists, and other healthcare providers to ensure that the data is interpreted accurately and applied in ways that truly benefit patients. There must also be robust infrastructure to securely store and manage genetic data while ensuring patient privacy and regulatory compliance [62]. Further research in this domain is ongoing.

The application of genetics in Orthopedics diseases offers a transformative opportunity to increase patient care and improve treatment results through personalized medicine. By applying genetic insights, clinicians can achieve earlier, more accurate diagnoses and develop treatment plans that are precisely tailored to each patient’s unique needs. However, to fully unlock the potential of personalized Orthopedics care, it is essential to address the challenges posed by genetic variability, accessibility, and integration into existing healthcare systems. Collaboration among geneticists, Orthopedics specialists, and healthcare providers is critical for ensuring that genetic data is correctly interpreted and applied in clinical settings. With continued innovation and thoughtful incorporation of genetic-based therapies into clinical practice, the future of Orthopedics medicine will be reshaped, resulting in better patient results, lower treatment costs, and an overall improved quality of life.

None.

No conflict of interest.

1. Luo Y (2024) Toward fully automated personalized orthopedic treatments: innovations and interdisciplinary gaps. Bioengineering 11(8): 817.
2. Stark Z, Scott R H (2023) Genomic newborn screening for rare diseases. Nat Rev Genet 24(11): 755-766.
3. Giuseppe M, Flavia C A, Marta A S, Michelino Di R, Paola C, Ali M (2015) Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and progression. Int J Mol Sci 16(3): 6093-6112.
4. Georgian-LI, Loredana I, Mihnea Ioan G P, Razvan-A C-B, Antonio-D C, Catalin C (2024) Genomic Determinants of Knee Joint Biomechanics: An Exploration into the Molecular Basis of Locomotor Function, a Narrative Review. Curr Issues Mol Biol 46(2): 1237-1258.
5. Yuta F, Lin L, Lisa Y, Maiko I, Tomoki C, Hiroshi A (2022) Cartilage homeostasis and osteoarthritis. Int J Mol Sci 23(11): 6316.
6. Joohyun L, Ingo G, Stefanie A, Brendan L (2017) Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone 102: 40-49.
7. Bertacco J (2023) Role of miR-204 and bioactive compounds in modulating chondrogenic and osteogenic differentiation of mesenchymal stem cells.
8. Swati G P, Jordan J K, Timothy Y, Lieu C H, Boland C R (2022) The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol 7(3): 262-274.
9. Joyce Bj van M, Cindy G B, Laura L-D, Jose A R (2019) Role of epigenomics in bone and cartilage disease. J Bone Miner Res 34(2): 215-230.
10. Qi-Fei W, Hong-Sen B, Ze-Lian Q, Pu W, Fang-Fei N, Guang-Wu Z (2020) Associations of LRP5 gene with bone mineral density, bone turnover markers, and fractures in the elderly with osteoporosis. Front Endocrinol 11: 571549.
11. Wysocki T, Olesińska M, Paradowska-Gorycka A (2020) Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis–from research to clinical practice. Cells 9(5): 1127.
12. Ginsburg GS, Willard H F, (2009) Genomic and personalized medicine: foundations and applications. Transl Res 154(6): 277-287.
13. Noor N M, Paula S, Stéphane P, Xavier R (2022) Early diagnosis, early stratification, and early intervention to deliver precision medicine in IBD. Inflamm Bowel Dis 28(8): 1254-1264.
14. Chadwick A, Andrew F, Talal W K, Erin Y (2021) Understanding the psychological, physiological, and genetic factors affecting precision pain medicine: a narrative review. J Pain Res 14: 3145-3161.
15. Zobdeh F, Ivan I E, Mikail A A, Vadim V T, Vladimir N C, Helgi B S et al., (2022) Pharmacogenetics and pain treatment with a focus on non-steroidal anti-inflammatory drugs (NSAIDs) and antidepressants: a systematic review. Pharmaceutics 14(6): 1190.
16. Rustam L B, Elliott D E, Ince M N (2024) Use of Laboratory Tests for Patients with Inflammatory Bowel Diseases. Manual of Molecular and Clinical Laboratory Immunology 2: 1071-1084.
17. Morrison N A, Peter M G, Tanya V, Murray W T, Chris M F, Nigel L G (2005) Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet Genomics 15(2): 127-135.
18. Bouillon R, Claudio M, Geert C, Daniel B, John H W, Bess D-H et al., (2019) Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev 40(4): 1109-1151.
19. Del Real Á, Carmen V, José M O, Jose L H, José A R (2022) Pharmacogenetics of Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs. Pharmaceutics 14(4): 776.
20. Scott S A (2011) Personalizing medicine with clinical pharmacogenetics. Genetics in medicine 13(12): 987-995.
21. Köstner K, Nicole D, Cornelia S L M, Rolf K, Wolfgang T, Jörg R (2009) The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 29(9): 3511-3536.
22. Dominguez L J, Mario F, Nicola V, Mario B (2021) Vitamin D sources, metabolism, and deficiency: available compounds and guidelines for its treatment. Metabolites 11(4): 255.
23. Natesan V, Kim S J (2022) Metabolic bone diseases and new drug developments. Biomol Ther 30(4): 309.
24. Suwinski P, ChuangKee O, Maurice H T L, Yang M P, Asif M K, Hui S O (2019) Advancing personalized medicine through the application of whole exome sequencing and big data analytics. Front Genet 10: 49.
25. Das S, Amit T, Anupam D, Ayaskant S, Sukanta B, Ashok K S (2025) Advances in Regenerative Medicine for Orthopedic Injuries: A Comprehensive Review Cureus 17(2): e79860.
26. Shirbache K, Nematian H, Nabian M H (2023) Regenerative medicine owes to microsurgery. Lab Anim Res 39(1): 6.
27. Kwon S G, Yang W K, Tae W L, Park G T, Jae H K (2018) Recent advances in stem cell therapeutics and tissue engineering strategies. Biomaterials research 22(36): 1-8.
28. Nematian H, Kamran S, Zahra V, Nesa M, Leila O Z, Masoumeh F et al., (2023) Regenerative Medicine in Orthopaedics: Microsurgery Achievements for Translational Animal Model. Open Journal of Regenerative Medicine 12(2): 21-35.
29. Grol M W, Lee B H (2018) Gene therapy for repair and regeneration of bone and cartilage. Current opinion in pharmacology 40: 59-66.
30. El Miedany Y (2022) Fundamentals and Applications of Regenerative Medicine, in Musculoskeletal Ultrasound-Guided Regenerative Medicine, Springer p. 3-24.
31. Rai V, Shahzad W M, Noman U W, Irum J (2024) Revolutionizing bone tumor management: cutting-edge breakthroughs in limb-saving treatments. Eur J Orthop Surg Traumatol 34(4): 1741-1748.
32. Alaribe F N, Manoto S L, Motaung S C (2016) Scaffolds from biomaterials: advantages and limitations in bone and tissue engineering. Biologia 71(4): 353-366.
33. Shirbacheh A, Shirbache K (2023) PMMA Bone Cement: Properties, Applications, and Innovations. Journal of Composites and Compounds 5(17).
34. Dzobo K, Nicholas E T, Dimakatso A S, Hendrina S, Arielle R, Collet D et al., (2018) Advances in regenerative medicine and tissue engineering: innovation and transformation of medicine. Stem cells Int 2018(1): 2495848.
35. Gomes S, Isabel B L, João F M, Rui L R, David L K (2012) Natural and genetically engineered proteins for tissue engineering. Prog Poly Sci 37(1): 1-17.
36. Liang J, Xinquan Y, Liang L, Yan Z, Qiong W, et al., (2023) Biomaterial-based scaffolds in promotion of cartilage regeneration: recent advances and emerging applications. J Orthop Translat 41: 54-62.
37. Haider A, Shabana K, Dure N I, Salah U K, Sajjad H, Khaled M et al., (2024) Chitosan as a tool for tissue engineering and rehabilitation: recent developments and future perspectives–A review. Int J Biol Macromol 278(Pt 1):134172.
38. Anitha A, Sowmya S, Sudheesh K P T, Deepathi S, Chennazhi K P, Ehrlich H, Tsurkan M et al., (2014) Chitin and chitosan in selected biomedical applications. Progress in polymer science 39(9): 1644-1667.
39. Watson-Levings RS, Glyn D P, Padraic P L, Anthony D E, Christopher H E, Steven C G (2022) Gene therapy in orthopaedics: progress and challenges in pre-clinical development and translation. Front Bioeng Biotechnol 10: 901317.
40. Medina-Cruz D, Ebrahim M, Ada Vernet-C, Junjiang C, Veer S, Jorge Luis C-D et al., (2020) Green nanotechnology-based drug delivery systems for osteogenic disorders. Expert Opin Drug Deliv 17(3): 341-356.
41. Maruelli S (2017) Gene therapy strategy for classical Osteogenesis Imperfecta due to mutations in COL1A2 gene.
42. Ranjbarnejad F, Mozafar K, Alireza S, Fatemeh K, Leila R (2022) Recent advances in gene therapy for bone tissue engineering. J Tissue Eng Regen Med 16(12): 1121-1137.
43. Liang Y, Xiao X, Limei X, Indira P, Li D, Yin X et al., (2021) Non-surgical osteoarthritis therapy, intra-articular drug delivery towards clinical applications. J Drug Target 29(6): 609-616.
44. Uebelhoer M, Cécile L, Juliane G, Kilian G, Stanislav P, Yves H (2023) Interleukins, growth factors, and transcription factors are key targets for gene therapy in osteoarthritis: a scoping review. Front Med 10: 1148623.
45. Yang Y, Zhang H (2024) Intra‐Articular Injection of Nanomaterials for the Treatment of Osteoarthritis: From Lubrication Function Restoration to Cell and Gene Therapy. Advanced Functional Materials 34(30): 2401547.
46. Mitchell M J, Margaret M B, Rebecca M H, Marissa E W, Nicholas A P, Robert L (2021)Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20(2): 101-124.
47. Hussen B M, Mohammad T, Raya K Y, Gaylany H A, Snur R A, Ramiar K K et al., (2024) Revolutionizing medicine: recent developments and future prospects in stem-cell therapy. Int J Surg 110(12): 8002-8024.
48. Baldari S, Giuliana D R, Martina P, Michela P, Maurizio M, Gabriele T (2017) Challenges and strategies for improving the regenerative effects of mesenchymal stromal cell-based therapies. Int J Mol Sci 18(10): 2087.
49. Wang L, Minjie R, Qiqi B, Chengzhu Z (2025) Signaling Pathways Driving MSC Osteogenesis: Mechanisms, Regulation, and Translational Applications. Int J Mol Sci 26(3): 1311.
50. Ljungqvist O, Scott M, Fearon K C (2017) Enhanced recovery after surgery: a review. JAMA surg 152(3): 292-298.
51. Chen Y, Rui-Juan C,Yinlan Wu,Deying H,Yanhong Li, Yi L (2023) Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis. Int J Mol Sci 25(1).
52. Freitas J, Susana G S, Raquel M G, José H T, Mário A B, Maria Inês A (2019) Genetically engineered-MSC therapies for non-unions, delayed unions and critical-size bone defects. Int J Mol Sci 20(14): 3430.
53. Loh K M, Angela C, Pang Wei K, Tianda Z D, Rahul S, Jonathan M T et al., (2016) Mapping the pairwise choices leading from pluripotency to human bone, heart, and other mesoderm cell types. Cell 166(2): 451-467.
54. Kumar R, Griffin M, Butler P (2016) A review of current regenerative medicine strategies that utilize nanotechnology to treat cartilage damage. Open Orthop J 10: 862.
55. Al Ali M (2024) Fundamentals of Orthopedic Design with Non-parametric Optimization: Springer.
56. Colhoun H M, McKeigue PM, Smith G D (2003)Problems of reporting genetic associations with complex outcomes. Lancet. 361(9360): 865-872.
57. Verstockt B, Parkes M, and Lee J C (2022) How do we predict a patient’s disease course and whether they will respond to specific treatments? Gastroenterology 162(5): 1383-1395.
58. Seritan A L (2023)The impact of climate change on older adults’ mental health: a primer for clinicians. OBM Geriatrics 7(4): 1-20.
59. Metcalfe S A (2018) Genetic counselling, patient education, and informed decision-making in the genomic era. Semin Fetal Neonatal Med 23(2):142-149.
60. Chanchal D K, Jitendra Singh C, Pushpendra K, Neha A, Prateek P (2024) CRISPR-based therapies: revolutionizing drug development and precision medicine. Curr Gene Ther 24(3): 193-207.
61. Francisco K K Y, Andrane Estelle C A, Myles Joshua T T, Mickael C B, Nicholle Mae Amor T M, Hezerul A K et al., (2024) Can Personalized Medicine Coexist with Health Equity? Examining the Cost Barrier and Ethical Implications. arXiv preprint arXiv:2411.02307.
62. Rinaudo O (2023) Leveraging AI for Secure Genomic Data in Precision Medicine: Cloud-Based Approaches in Healthcare Innovation.